BFSG LLC’s Lineage Cell Therapeutics LCTX Stock Holding History

BFSG LLC’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-355	Closed	-$526	–	652
2024 Q1	$526	Buy	+355	New	+$402	﹤0.01%	630

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BFSG LLC's LCTX Position: Q2 2024 in Review

BFSG LLC sold out of Lineage Cell Therapeutics (LCTX) in Q2 2024, closing a stake of 355 shares — an estimated $526 sold.

BFSG LLC first reported a position in LCTX in Q1 2024 and held it in 1 quarter. The position peaked at $526 in Q1 2024. 113 funds tracked by Wall St. Rank hold LCTX as of Q2 2024.

BFSG LLC reported no remaining Lineage Cell Therapeutics position as of Q2 2024 after selling out during the quarter.
BFSG LLC sold 355 Lineage Cell Therapeutics shares in Q2 2024, an estimated $526.
BFSG LLC first reported a position in Lineage Cell Therapeutics in Q1 2024 and held it in 1 quarter.
BFSG LLC's Lineage Cell Therapeutics position peaked at $526 in Q1 2024.
113 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2024.

Based on BFSG LLC's 13F filing for Q2 2024, filed 29 Jul 2024.